NCT02675439 2021-12-30Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or LymphomasChinook Therapeutics, Inc.Phase 1 Terminated47 enrolled
NCT01986426 2018-10-03LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or PembrolizumabLytix Biopharma ASPhase 1 Completed80 enrolled